Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;8(4):337-40.

Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study

Ramin Nourinia  1 , Hamid Ahmadieh  1 , Mohammad-Hassan Shahheidari  1 , Souska Zandi  2 , Shintaro Nakao  2 , Ali Hafezi-Moghadam  2
Affiliations

Intravitreal fasudil combined with bevacizumab for treatment of refractory diabetic macular edema; a pilot study

Ramin Nourinia et al. J Ophthalmic Vis Res. 2013 Oct.

Abstract

Purpose: To evaluate the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor (Fasudil, Asahi Kasei Pharma Corporation, Tokyo, Japan) combined with intravitreal bevacizumab (IVB) on refractory diabetic macular edema (DME).

Methods: This prospective, interventional case series included 15 eyes of 15 patients with DME unresponsive to previous IVB injections. Eligible eyes underwent intravitreal injection of 0.025 mg Fasudil and 1.25 mg bevacizumab. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated before and 4 weeks after treatment.

Results: Mean age was 64.6±7.3 (range, 49-79) years and mean number of previous IVB injections was 2.8. Mean pre-injection BCVA was 0.84±0.35 LogMAR, which was improved to 0.49±0.29 LogMAR four weeks after intervention (P=0.003). Mean CMT was decreased from 448±123 µm before treatment, to 347±76 µm at four weeks (P=0.001); no adverse event was observed during the study period.

Conclusion: Intravitreal ROCK inhibitors seem to entail structural and visual benefits in eyes with DME refractory to IVB monotherapy.

Keywords: Angiogenesis; Diabetic Macular Edema; Rho Kinase.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Optical coherence tomography images of three patients (A, B and C) show significant reduction of central macular thickness (CMT) one month after intravitreal injection of bevacizumab and Fasudil. CMT before treatment (top images) was 559, 516 and 455 μm decreasing to 281, 344 and 330 μm one month after treatment (lower images) in patients A, B and C, respectively.
See this image and copyright information in PMC

References

    1. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo - controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2008;246:483–489. - PubMed
    1. Shoeibi N, Ahmadieh H, Entezari M, Yaseri M. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: long-term results of a clinical trial. J Ophthalmic Vis Res. 2013;8:99–106. - PMC - PubMed
    1. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24- month data: report 3. Arch Ophthalmol . 2012;130:972–979. - PubMed
    1. Mehta S, Blinder KJ, Shah GK, Kymes SM, Schlief SL, Grand MG. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010;41:323–329. - PubMed
    1. Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, et al. Long- term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Retina. 2008;28:1053–1060. - PubMed

LinkOut - more resources